STOCK TITAN

United Therapeutics Corporation to Present at the UBS Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

United Therapeutics (UTHR) announced its participation in the UBS Global Healthcare Conference in Rancho Palos Verdes, CA. Patrick Poisson, Executive Vice President of Technical Operations, will present a company update during a fireside chat on Tuesday, November 12, 2024, from 2:45 PM to 3:20 PM PST.

The session will be accessible through a live webcast on the company's website, with a recorded version available for 180 days after the event. United Therapeutics, operating as a public benefit , focuses on developing novel pharmaceutical therapies and technologies to increase transplantable organ availability.

United Therapeutics (UTHR) ha annunciato la sua partecipazione alla Conferenza Sanitaria Globale UBS a Rancho Palos Verdes, CA. Patrick Poisson, Vice Presidente Esecutivo delle Operazioni Tecniche, presenterà un aggiornamento dell'azienda durante un incontro informale il martedì 12 novembre 2024, dalle 14:45 alle 15:20 PST.

La sessione sarà accessibile attraverso un webcast dal vivo sul sito web dell'azienda, con una versione registrata disponibile per 180 giorni dopo l'evento. United Therapeutics, operando come azienda di pubblica utilità, si concentra sullo sviluppo di nuove terapie e tecnologie farmaceutiche per aumentare la disponibilità di organi trapiantabili.

United Therapeutics (UTHR) anunció su participación en la Conferencia Global de Salud de UBS en Rancho Palos Verdes, CA. Patrick Poisson, Vicepresidente Ejecutivo de Operaciones Técnicas, presentará una actualización de la empresa durante una charla informal el martes 12 de noviembre de 2024, de 2:45 PM a 3:20 PM PST.

La sesión será accesible a través de una transmisión en vivo en el sitio web de la empresa, con una versión grabada disponible durante 180 días después del evento. United Therapeutics, que opera como una organización de beneficio público, se enfoca en desarrollar nuevas terapias y tecnologías farmacéuticas para aumentar la disponibilidad de órganos transplantables.

United Therapeutics (UTHR)는 CA의 Rancho Palos Verdes에서 열리는 UBS 글로벌 헬스케어 컨퍼런스에 참가한다고 발표했습니다. 기술 운영 부사장인 Patrick Poisson이 2024년 11월 12일 화요일 오후 2시 45분부터 3시 20분 PST까지 회사 업데이트를 발표할 예정입니다.

세션은 회사 웹사이트에서 생중계로 확인할 수 있으며, 이벤트 후 180일 동안 녹화된 버전도 제공됩니다. United Therapeutics는 공공 이익을 목표로 활동하며, 이식 가능한 장기 가용성을 높이기 위해 새로운 제약 치료법과 기술을 개발하는 데 주력하고 있습니다.

United Therapeutics (UTHR) a annoncé sa participation à la Conférence Mondiale sur la Santé UBS à Rancho Palos Verdes, CA. Patrick Poisson, Vice-Président Exécutif des Opérations Techniques, présentera une mise à jour de l'entreprise lors d'un entretien informel le mardi 12 novembre 2024, de 14h45 à 15h20 PST.

La session sera accessible via un webinaire en direct sur le site internet de l'entreprise, avec une version enregistrée disponible pendant 180 jours après l'événement. United Therapeutics, qui opère en tant qu'organisation à but public, se concentre sur le développement de nouvelles thérapies pharmaceutiques et technologies pour augmenter la disponibilité des organes transplantables.

United Therapeutics (UTHR) hat seine Teilnahme an der UBS Global Healthcare Conference in Rancho Palos Verdes, CA, angekündigt. Patrick Poisson, Executive Vice President für Technische Operationen, wird am Dienstag, den 12. November 2024 von 14:45 bis 15:20 Uhr PST ein Unternehmensupdate während eines informellen Gesprächs präsentieren.

Die Sitzung wird über ein Live-Webcast auf der Unternehmenswebsite zugänglich sein, mit einer aufgezeichneten Version, die 180 Tage nach der Veranstaltung verfügbar ist. United Therapeutics, das als öffentliche Wohltätigkeitsorganisation operiert, konzentriert sich auf die Entwicklung neuartiger pharmazeutischer Therapien und Technologien zur Erhöhung der Verfügbarkeit von transplantierbaren Organen.

Positive
  • None.
Negative
  • None.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Patrick Poisson, Executive Vice President, Technical Operations, will provide an overview and update on the company’s operations during a fireside chat session at the UBS Global Healthcare Conference in Rancho Palos Verdes, CA.

The session will take place on Tuesday, November 12, 2024, from 2:45 p.m. to 3:20 p.m., Pacific Standard Time, and can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations. An archived, recorded version of the session will be available approximately 24 hours after the session ends and can be accessed for 180 days.

United Therapeutics: Enabling Inspiration

At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun, we do good. We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC). Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs.

You can learn more about what it means to be a PBC here: unither.com/pbc.

Forward-Looking Statements

Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, our efforts to innovate for the unmet medical needs of our patients, to benefit our other stakeholders, and to pursue our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language, and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of November 5, 2024, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.

Dewey Steadman at (202) 919-4097 (media/investors)

Harry Silvers at (301) 578-1401 (investors)

https://ir.unither.com/contact-ir

Source: United Therapeutics Corporation

FAQ

When is United Therapeutics (UTHR) presenting at the UBS Global Healthcare Conference 2024?

United Therapeutics will present on Tuesday, November 12, 2024, from 2:45 PM to 3:20 PM Pacific Standard Time.

Who will represent UTHR at the UBS Global Healthcare Conference 2024?

Patrick Poisson, Executive Vice President of Technical Operations, will represent United Therapeutics at the conference.

How can investors access UTHR's presentation at the UBS Healthcare Conference?

Investors can access the presentation via live webcast at https://ir.unither.com/events-and-presentations, with a recorded version available for 180 days after the event.

What is United Therapeutics' (UTHR) public benefit purpose?

UTHR's public benefit purpose is to provide a brighter future for patients through novel pharmaceutical therapies and technologies that expand transplantable organ availability.

United Therapeutics Corp

NASDAQ:UTHR

UTHR Rankings

UTHR Latest News

UTHR Stock Data

16.35B
43.82M
1.85%
101%
5.16%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SILVER SPRING